Viking Therapeutics (NASDAQ:VKTX) has become one of Wall Street’s most tempting biotech stories because its obesity drug could make it a major buyout target. The upside is easy to understand, especially as Medicare access could expand demand for weight loss drugs. But the stock also carries a serious catch: Viking has no approved product yet, and a rival may already be moving faster.
Stock prices used were the market prices of June 26, 2026. The video was published on July 7, 2026. On the date of publication, Rick Orford did not have (either directly or indirectly) positions in any of the securities mentioned in this video.
